Bartosz Hudzik: Extended Anticoagulation in Cancer-Associated VTE – Who Is at Higher Bleeding Risk?
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn about a recent article by Isabelle Mahé et al, published in The Lancet Haematology:
”Extended anticoagulation in cancer-associated VTE: who is at higher bleeding risk?
Extended anticoagulation with reduced-dose apixaban has been shown to be non-inferior to full-dose therapy for preventing recurrent VTE in patients with active cancer—while offering fewer clinically relevant bleeding events.
A new post-hoc analysis of the API-CAT trial takes a closer look at predictors of clinically relevant bleeding during extended therapy.
Key findings (12-month follow-up, n=1,766):
Four factors were independently associated with increased bleeding risk:
• Anaemia and/or thrombocytopenia
• Age ≥75 years
• Pulmonary embolism as the index event
• Male sex
Notably:
• Results were consistent across cancer types
• No interaction with apixaban dose was observed
Why this matters
Although API-CAT was not designed to guide anticoagulation discontinuation, these insights may help clinicians better individualize extended anticoagulation, balancing thrombotic protection against bleeding risk in patients with cancer-associated VTE.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti for the API-CAT Study Group and API-CAT Investigators
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 14:13Shahzeb Hassan: Pulmonary Embolism – What to Do When Every Minute Matters
-
Apr 15, 2026, 14:06Hossam El Benawi: Intensive Blood Pressure Reduction May Worsen Outcomes After Thrombectomy
-
Apr 15, 2026, 13:51Matías J Alet: Hospital Carlos Saporiti on the Path to Essential Stroke Center Recognition
-
Apr 15, 2026, 13:39Congratulations to Sandy Middleton for Taking the 2026 HESTA Australian Nursing and Midwifery Awards – Stroke Foundation
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk